drugset / Trial / NCT00395291
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients
Completed
49 enrolled
University of Virginia
Merck Sharp & Dohme LLC · collabNational Institutes of Health (NIH) · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The objective of this study is to determine MK-0677 increases IGF-1 in patients with end stage renal disease (ESRD) on hemodialysis.
Timeline
- Start
- 2006-08
- Primary completion
- 2009-01
- Completion
- 2010-05
Outcome
Met primary endpoint
registry MEAN MK-0677: 92.7 (Standard Deviation 62.3) ng/ml MEAN Placebo: 6.7 (Standard Deviation 40.2) ng/ml NCT00395291 ↗
registry MK-0677 vs Placebo; p <0.001; ANCOVA NCT00395291 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibutamoren | Small molecule | 25 mg | Oral |